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Abstract Nuclear receptors (NRs) are ligand dependent
transcriptional factors and play a key role in reproduction,
development, and homeostasis of organism. NRs are
potential targets for treatment of cancer and other diseases
such as inflammatory diseases, and diabetes. In this study,
we present a comprehensive library of pocket conforma-
tional ensembles of thirteen human nuclear receptors
(NRs), and test the ability of these ensembles to recognize
their ligands in virtual screening, as well as predict their
binding geometry, functional type, and relative binding
affinity. 157 known NR modulators and 66 structures were
used as a benchmark. Our pocket ensemble library cor-
rectly predicted the ligand binding poses in 94% of the
cases. The models were also highly selective for the active
ligands in virtual screening, with the areas under the
ROC curves ranging from 82 to a remarkable 99%. Using
the computationally determined receptor-specific binding
energy offsets, we showed that the ensembles can be used
for predicting selectivity profiles of NR ligands. Our results
evaluate and demonstrate the advantages of using receptor
ensembles for compound docking, screening, and profiling.
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Introduction
The primary function of nuclear receptors (NR) is to act as
transcriptional switches responding to lipophilic hormones,
vitamins, dietary lipids, or other intracellular signals [1, 2].
The common modular structure of an NR includes a conserved
N-terminal DNA-binding domain (DBD), and a C-terminal
ligand-binding domain (LBD) [3]. The DBD directly interacts
with DNA response element on the target genes to modulate
transcription. The role of the LBD is to recognize ligands and
coregulators [4]. Ligand binding to NRs LBD induces changes
in the conformational equilibrium and dynamic behavior of
receptors and regulates the recruitment of coregulators and
chromatin-modifying machineries [5, 6].
Nuclear receptors can be classified into the three groups.
The first is the classic and the most extensively charac-
terized group of receptors that respond to steroid hormones,
thyroid hormone (thyroid hormone receptor; TR), and
vitamins A (retinoic acid receptors; RAR) and D (vitamin
D receptor; VDR). These receptors are all essential for
homeostatic control of endocrine system. The second class
is the orphan nuclear receptors, which are structurally
related to nuclear hormone receptors but lack known nat-
ural ligands. In this group, nerve growth factor-induced
clone B (Nur77), nuclear receptor related-1 (Nurr1), and
neuronderived orphan receptor-1 (NOR1) are involved in
the inflammatory processes [7]. The third class of nuclear
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receptors includes adopted orphan nuclear receptors, which
function as heterodimers with retinoid X receptor (RXR).
These include receptors for fatty acids (peroxisome
proliferator activated receptors; PPARa, d, c), oxysterols
(liver X receptors: LXRa, b), bile acids (farnesoid X
receptor; FXR), xenobiotics (steroid and xenobiotic recep-
tor/pregnane X receptor; SXR/PXR [8]) and constitutive
androstane receptor; CAR) [9].
NRs are transcription factors naturally switched on and
off by small-molecule hormones. These hormones often
present physicochemical properties very similar to thera-
peutic chemical entities. As such, NRs represent an
important class of drug targets that have potential appli-
cations in cancer, inflammatory diseases, and diabetes.
Several NRs are already targeted by known drugs, such as
tamoxifen, a partial antagonist of estrogen receptor (ER), or
bicalutamide, an antagonist of androgen receptor (AR) used in
treatment of breast and prostate cancer, respectively [10, 11].
Progesterone receptor (PR) agonists have several important
applications in women’s health, such as in oral contraception
and post-menopausal hormone replacement therapy [12].
Spirolactones are mineralocorticoid receptor (MR) antago-
nists that have been used in the treatment of sodium-retaining
states and as antihypertensive agents [13]. The therapeutic
applications of vitamin D metabolites are treatments for renal
osteodystrophy, osteoporosis, psoriasis, cancer, autoimmune
disease, or prevention of graft rejection [14].
The rapid growth of the number of high quality crystal
structures of ligand binding domains of a number of
important nuclear receptors [15–18] creates an opportunity
to build a foundation for structure-based identification of
potential nuclear receptor agonists, antagonists, or tissue
selective modulators [19]. The incorporation of multiple
conformers of the same ligand binding pocket, a.k.a.
ensemble docking [20] results in a higher quality algorithms
for ligand binding pose prediction, virtual compound
screening, and selectivity profiling. The recently developed
4D docking technology [21] further improves this process
by dramatically speeding up all computational steps.
We have previously demonstrated the use of multiple
receptor model-based Virtual Ligand Screening for the
structure-based discovery of selective small molecule
antagonists of the androgen receptor [22] and the thyroid
hormone receptor [23], as well as antagonists [24] and ago-
nists [25] of the retinoic acid receptor RARa. In the present
paper we provide comprehensive benchmarking of the
approach using a large library of the conformational
ensembles of NR ligand binding pockets with determined
three-dimensional structures. We demonstrate the excep-
tional performance of the ensemble docking approach on the
tasks of predicting the ligand poses, test the ability of the
ensembles to recognize their ligands in virtual screening, and
propose a method to evaluate ligand selectivity profiles.
Methods
Preparation of receptor structures
Co-crystal structures of ligand binding domains (LBD) of the
progesterone receptor (PR), the mineralocorticoid receptor
(MR), vitamin D receptor (VDR), the androgen receptor (AR),
the peroxisome proliferator activated receptor alpha, beta,
gamma (PPARa, b, c), the estrogen receptor alpha, beta (ER
a,b), the retinoic acid receptor gamma (RARc), the gluco-
corticoid receptor (GR), the thyroid receptor (TR b), the ret-
inoid X receptor alpha (RXRa) were used for this study. PDB
entries with X-ray resolution [3 A˚ were excluded. When
several crystal structures were available for a specific recep-
tor/compound complex, the better resolution entry was taken.
PDB files were converted into the internal coordinate
representation using the Internal Coordinate Mechanics
(ICM) method [26]. In the process of conversion, hydrogen
atoms and missing heavy atom were built; polar hydrogens
were sampled to optimize the hydrogen-bonding networks.
Low occupancy side chains were optimized and assigned
the lowest energy conformation. Orientations of ambigu-
ously placed amino acids such as histidine, glutamine and
asparagine were optimized to improve the hydrogen
bonding patterns. For all NRs except ER only active
(agonist-bound) conformations were tested in this study. In
case MR and AR, wild type ligand binding domains were
studied along with therapeutically relevant point mutants.
Generation of nuclear receptor ligand database
The database included 157 known ligands including agonists,
antagonists, and selective nuclear receptor modulators. The
molecules were taken from recent publications. For each
receptor screened, between three and twenty-three known
active ligands were included in the database. Most ligands
targeted one of the library receptors, but several ligands had
annotated activity against several receptors. Compounds were
converted into 3D representation by the ICM conversion
procedure. Bond order, tautomeric form, stereochemistry,
hydrogen atoms and protonation state were assigned auto-
matically. Each ligand was assigned the MMFF [27] force
field atom types and charges and was then subject to Cartesian
minimization. The free molecules were optimized with global
energy in the internal coordinate space by the ICM method
[26, 27]. This procedure guaranteed that the docking proce-
dure did not have any memory of the bound conformation of
the ligands.
Internal coordinates mechanics grid docking
Ligand docking simulations were carried out using ICM
molecular modeling software (Molsoft LLC, La Jolla, CA)
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[26, 27] based on the Biased Probability Monte Carlo
(BPMC) simulations. ICM docking procedure performs
optimization of the ligand internal coordinates in the set of
grid potential maps of the receptors [28]. The ligand
binding pocket of each receptor was represented by pre-
calculated potential grid maps with grid step of 0.5 A˚. The
potentials including three van der Waals grid potential (for
a carbon probe, large atom probe, or hydrogen probe), a
hydrogen bonding grid potential, an electrostatic grid
potential, and a hydrophobic grid potential. Ligands were
sampled in the obtained maps. The sampling time ranged
from 20 s to 3 min per ligand per processor. All calcula-
tions were carried out on Intel Core 2 Duo 2.40 GHz.
In the single receptor docking mode, ligands were docked
independently into each receptor conformation and score
according to ICM full-atom scoring scheme [29]. In the
ensemble mode, docking poses of each ligand in all ensemble
structures were merged in a single hit list, and the ligand was
represented by the top-scoring pose in that list.
ICM full atom scoring
The ICM scoring [28, 29] function was previously derived
as a compromise between Gibbs binding energy and
numerical errors. It is calculated as follows:
Ebind ¼ DEIntFF þ TDSTor þ a1DEHBond þ a2DEHBDesol
þ a3DESolEl þ a4DEHPhob þ a5QSize
where ai are ligand- and receptor independent constants.
DEIntFF includes the van der Waals interaction of the ligand
with the receptor as well as internal force-field energy of the
ligand. TDSTor is the change in free energy due to the con-
formational entropy loss for the ligand upon binding. DEH-
Bond, DESolEl, DEHBDesol, DEHPhob and QSize are the hydrogen
bonding, the solvation electrostatic energy, the hydrogen
bond donor/acceptor desolvation correction, the hydropho-
bic terms, respectively, and QSize is the number of ligand
non-hydrogen atoms.
Virtual ligand screening
The ICM virtual ligand screening module was used. The
ligand database was docked into each protein structure. The
top scoring pose per ligand was refined and rescored.
The accuracy of VLS was tested as the area under the ROC
curves obtained plotting the number of false positives vs.
the number of true positives in the hit list.
Determination of NRs specific binding energy offsets
For each nuclear receptor NRk in the benchmark (k = 1, 2,
…, 17), the initial binding score offset was determined as the
negative 5% percentile threshold of the database compounds
binding scores. In other words, all compounds in the database
were scored and rank-ordered the ensembles of NRk, pro-
ducing the set or scores S (Cmpdi, NRk) (i = 1, 2, …,157,
k = 1, 2,…,17). The threshold Tk was defined so that 5% of
the database compounds had scores below this threshold.
The new scores for all compounds were calculated as Soff
(Cmpdi, NRk) = S (Cmpdi, NRk) - Tk.
The optimized NR-specific offsets were obtained by the
Nelder-Mead simplex [30] optimization of the normalized
ROC AUC on the matrix of scores Soff (Cmpdi, NRk) as a
function of the vector of offsets (T1, T2, …, T17). The
available experimental data on compounds activity was
used to define true positives, false positives, true negatives,
and false negatives. The initial offsets were scattered by
addition of random vector of numbers in the ranges of
[-10, 10] and used as multiple starting point for optimi-
zation. The obtained optimal combination of offsets pro-
vided discrimination of binders from non-binders with
ROC AUC as high as 90%.
Results
Building a library of structurally distinct high-quality
conformational ensembles of nuclear receptor pockets
We collected a library of high-quality crystallographic
structures of ligand binding domains of various human
nuclear receptors to be used in virtual screening and
selectivity profiling of NR ligands. Each receptor was
represented by an ensemble of structures rather than a
single structure in order to capture possible conformational
variations of the binding pocket. For four receptors,
estrogen receptors ERa and ERb, mineralocorticoid
receptor MR, and androgen receptor AR, we built more
than one ensemble.
In case of the estrogen receptors ERa and ERb, separate
ensembles represented active and inactive conformations.
Depending on the nature of the bound ligand (agonist or
antagonist), the carboxy-terminal helix H12 was found in
one of two orientations. In the agonist-bound conformation,
it serves as a ‘‘lid’’ to close the ligand-binding pocket,
whereas in the antagonist-bound conformation, this helix is
positioned in a different orientation opening the entrance to
the LBP. The classification was performed based on the
conformational analysis rather than on the nature of the
crystallized ligand. For example, even though genistein, is
an agonist of ERb, the co-crystal structure (PDB ID: 1qkm
[31]) was classified as inactive because of the observed
position of H12.
In case of mineralocorticoid receptor MR, all wild-type
structures were merged into one ensemble, while all
J Comput Aided Mol Des (2010) 24:459–471 461
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structures carrying a clinically relevant S810L point
mutation formed the second ensemble. This mutation is
known to cause severe hypertension, increase the stability
of ligand-MR complexes, and change the mode of action of
existing antagonists converting them into agonists. For
example, progesterone and spironolactone (Fig. 1), antag-
onists of the wild-type mineralocorticoid receptor [32, 33],
act as agonists of S810L MR [34]. Similar situation was
observed for the androgen receptor AR, as T877A point
mutation allows antagonists of the wild-type receptors to
invoke the agonist-bound conformation of the ligand
binding domain [35, 36].
For other receptors, the identified point mutations did
not change the mode of binding and action of the existing
ligands. By this reason, the mutant structures were included
in the same ensemble as the wild-type structures.
The structures were further analyzed and filtered to
retain only high-resolution (\2.9 A˚) X-ray structures that
reproduced the binding geometry of their cognate ligands
in docking. All protein structures in the ensemble were
superimposed using all atoms in the immediate vicinity of
the ligands. The superimposition algorithm was based on
an iterative procedure that, through an unbiased weight
assignment to different atomic subsets, gradually found the
better superimposable core of atom pairs between the
template and the other structures. The energy-based pre-
processing and refinement of the structures was performed
that included selection of optimal His tautomers, prediction
of orientation of Asn, Gln and His residues, and optimi-
zation of polar hydrogen atoms in order to reproduce cor-
rect hydrogen bonding networks. The resulting library of
NR structure ensembles is summarized in Table 1. It
includes 17 ensembles of 13 nuclear receptors, with three
to six structures per ensemble (65 structures total).
Prediction of ligand binding geometry by single
receptor cross-docking
We first studied the ability of the collected pocket struc-
tures to correctly reproduce the binding geometry of their
cognate ligands and other ligands in their ensembles. The
flexible compound docking and scoring was performed
using the Internal Coordinate Mechanics (ICM) algorithm
described in Methods. As the criterion of correct binding
pose prediction, the standard ligand heavy-atom RMSD
cutoff of 2 A˚ was used. As we expected, all ligands were
reproduced correctly within 2A˚ RMSD in the self-docking
(Fig. 2 and Table 2).
In cross docking, 63 compounds were docked into the
structures of their target receptors, with the cognate
(co-crystallized) structure excluded. That made the total of
256 structure-ligand pairs. As shown in Fig. 2, the near-
native ligand conformation scored at the top in 202 cases
(78%), and was found within three top-scoring poses in 220
cases (85%). The success rate of ligand binding pose pre-
diction for individual receptors is shown in the Table 2.
Most importantly, the predicted ligand poses correctly
captured most or all essential ligand-receptor contacts
predicted by crystallography, mutagenesis, and quantum
mechanical studies [37–39]. This makes the predicted
poses good starting points for compound optimization or
understanding effects of pocket residue modifications.
Improved prediction of ligand binding geometry
by ensemble docking
In multiple receptor conformation, or ensemble docking,
alternative docking poses of a single ligand from different
receptor structures were combined in a single hit list, and
the ligand was represented by the best scoring pose in this
list. The cognate receptor structure was excluded from the
ensemble. As shown in Fig. 2, ensemble docking with
excluded cognate receptor structure reproduced the near-
native ligand binding geometry as the top-scoring pose in
89% of the cases (56 out of 63 receptor-ligand pairs). 36
of 63 best scoring poses of each ligand in its receptor
ensemble are shown in Fig. 3 (the rest of poses can be
found in supporting information Figure S2). For three
more cases (PPARd/GNI, PPARc/EHA and ERa-/E4D),
the correct geometry was found within three top scoring
poses in the hit list. The result of this section confirms
that using experimentally determined structure ensembles
with small number of conformers improves docking
accuracy as compared to single receptor mode (89%Fig. 1 Chemical structures of compounds mentioned in the text
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success rate in ensemble docking vs. 78% in single
receptor docking).
Successful recognition of active compounds by the NR
pocket ensembles in virtual screening
We tested the ability of the NR pockets and their confor-
mational ensembles to select the active ligands of their
respective receptors from a large and challenging com-
pound database. Docking and scoring the database com-
pounds in a single pocket or a pocket ensemble produced
an ordered hit list. The screening selectivity of the models
is represented by their ability to bring the active com-
pounds to the top of the list, and is evaluated numerically
as the Area Under normalized Receiver Operating Char-
acteristic (ROC) curve, or AUC.
The ligand database was collected as described in
Methods. It consisted of 157 various nuclear receptor
ligands described in literature. 124 of these compounds had
annotated agonist or antagonist activity against at least one
of the library receptors (supplementary information
Table 1). For each receptor, between three and twenty-
three known ligands were included in the database. Most
compounds in the database targeted exactly one receptor,
but for some of them the activity against two or more
receptors was described in literature.
In the single pocket mode, 29 out of 66 NR structures
(43%) showed high selectivity towards their respective
ligands with ROC-AUC exceeding 90%. For 53 structures
(80%) ROC-AUC exceeded 80%. The results of VLS with
single pocket conformation are summarized in Table 3.
When used in the ensemble mode, the ligand hit lists
from different structures in the ensemble were combined
and each ligand was represented by its best score in the
ensemble. This remarkably improved the screening per-
formance of our NR structure library. For 11 of 17
ensembles, ROC-AUC values of more than 90% were
achieved, and for others they exceeded 80%. The most
significant improvement was obtained for ERa-,
ERb- and PR? which showed poor selectivity in the
single receptor mode, but achieved the ROC AUC values
of 86, 87 and 92% respectively, in the ensemble mode
(Fig. 4). This result suggests that ensemble screening is the
most efficient approach to VLS.
Variations in the screening selectivity of the individual
ensembles can be in part explained by the incompleteness
of our ligand benchmark set. Because in the absence of
information on binding of a particular ligand to a receptor
of interest we assumed that the ligand is inactive, low
Table 1 Composition of the nuclear receptor library
Ensemble ID Description PDB IDs and co-crystallized ligand Het IDs
1 ERa- Estrogen receptor a, inactive conformation 1xp6 (AIU), 1xqc_a (AEJ), 1sj0 (E4D), 2ouz (C3D)
2 ERa? Estrogen receptor a, active conformation 2b1v_a (458), 2b1z_a (17M), 2fai_a (459), 1l2i_a (ETC.)
3 ERb- Estrogen receptor b, inactive conformation 1hj1 (AOE), 1qkm (GEN), 1qkn (RAL)
4 ERb? Estrogen receptor b, active conformation 1u3r_a (338), 1yy4_a (4NA), 1zaf_b (789)
5 GR? Glucocorticoid receptor, agonist—bound 1m2z_a (DEX), 1p93_a (DEX), 3bqd (DAY)
6 wtMR? Mineralocorticoid receptor, agonist—bound 2aa7 (1CA), 2a3i (C0R), 2aa2 (AS4),
7 S810L MR? Mineralocorticoid receptor, agonist—bound 1y9r_a (1CA), 2aa6_a (STR), 1ya3_a (STR), 2aax_a (STR)
8 PR? Progesterone receptor, agonist—bound 1e3k _a(R18), 1zuc_b (T98), 2ovh (AS0)
9 RARc? Retinoic acid receptor c, agonist—bound 1exa (394), 1fcx (184), 2lbd (REA)
10 RXRa? Retinoic acid receptor a, agonist—bound 1fm9 (REA), 1mzn_a (BM6), 1rdt (L79), 1xvp_a
(CID), 2p1u (4TN)
11 VDR? Vitamin D3 receptor, a agonist—bound 1db1 (VDX), 1s19 (MC9), 1txi (TX5), 2har (OCC),
2has (C3O), 2hb7 (O1C)
12 wtAR? Androgen receptor, agonist—bound 1e3g (R18), 2am9 (TES), 1t7t (DHT), 2hvc (LGD)
13 T877A AR? Androgen receptor, agonist—bound 1gs4 (ZK5), 2ax7 (FHM), 2oz7 (CA4)
14 PPARa? Peroxisome proliferator-activated receptor a,
agonist—bound
2npa_c (MMB), 2rew (REW), 2p54 (735), 1k7l_a (544),
15 PPARd? Peroxisome proliferator-activated receptor d,
agonist—bound
1gwx_a (433), 1y0s_a (331), 2j14_b (GN1)
16 PPARc? Peroxisome proliferator-activated receptor c,
agonist—bound
1rdt (L79),1k74 (544), 1knu (YPA), 1nyx (DRF),
2f4b (EHA), 2gtk (208)
17 TRb? Thyroid hormone receptor b, agonist—bound 1n46_b (PFA), 1nax (IH5), 1q4x (G24), 2h6w (T3)
(?): agonist-bound or active state, (-): antagonist-bound or inactive state
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docking score for that ligand was automatically classified
as a false positive. Further examination of several false
positives confirmed their activity against the target thus
qualifying them as true positives instead. That was the
case, for example, for diethylstilbestrol for which ERa
agonist activity was confirmed after docking by literature
search [40]. Additionally, a number of false positives in the
benchmark were due to the fact that antagonist (inactive)
binding pockets are often sterically compatible with the
agonist molecules (but not vice versa) and share significant
subsets of interactions. The use of pharmacophore-like
atomic property fields in the spirit of [41, 42] may help to
distinguish and eliminate this ambiguity.
False negatives, i.e. active compounds with poor dock-
ing scores may also affect the evaluation of the overall
selectivity of the ensembles. Our structural ensembles are
able to capture some, but not all aspects of the receptor
equilibrium, especially for flexible pockets like ERa. In
Fig. 2 Self- and cross-docking of crystallographic compounds into
individual pockets of the proposed NR pocket library. The table
entries are colored by Rmsd of the compound docking poses from the
crystallographic poses: green—correct pose is ranked first; blue—
correct pose is found within top three; pink—correct pose is not found
within top three poses. Empty circle—cognate ligand (hence self-
docking); filled circle—top score in the ensemble. All compound
chemical structures can be found in Supplementary information
Figure S1
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such cases, addition of new experimental conformations as
they become available may help improve the quality of the
compound recognition.
Determination of protein-dependent binding free
energy offsets for compound selectivity profiling
Ligand selectivity profiling is a very challenging task of
computational structural biology that requires an accurate
prediction of relative binding energy estimate of a single
compound to different receptors. It is orthogonal to the task
of screening, which is based on prediction of binding
energies of a single receptor to multiple database com-
pounds. It has been previously shown that intrinsic prop-
erties of the proteins, such as protein entropy loss upon
ligand binding, structure quality fluctuations, and inevita-
ble errors in energy functions can be, to a certain level,
absorbed into a single protein-dependent binding energy
offset which can be pre-calculated using experimentally
observed binding energies or statistical considerations [42].
Such offsets must be applied in compound selectivity
profiling.
There are several ways to determine the offsets. The
easiest, naı¨ve way is based on the distribution of calculated
binding scores of all database compounds in a given
ensemble, and does not depend on any experimental data
about active compounds. A single offset is calculated for
each ensemble and applied in such a way that exactly 5%
of all database compounds have binding scores better than
a single fixed threshold. A better, more precise way to
determine the offset is based on analysis of existing
experimental compound activity data. The offsets (one
number for each ensemble) are obtained by a machine
learning algorithm that optimizes the recognition of correct
targets for all database compounds.
In this work, we derived the protein-specific binding
energy offsets in both ways, applied them to the predicted
ligand binding energies, and evaluated the ligand speci-
ficity profiling accuracy of the obtained models. Figure 5
presents the comparison of the naı¨ve offsets with those
derived by simplex minimization of the total number of
errors in the receptor-ligand binding matrix. It is clear that
the naı¨ve offsets are sufficiently close to the trained offsets
(R2 = 0.64) and, therefore, represent a reasonable
approximation of the true offsets to be used in compound
profiling.
Ligand selectivity profiling using the structure library
and the precalculated binding energy offsets
We found that even raw ICM docking scores were pre-
dictive of compound selectivity profiles. This is demon-
strated by Fig. 6a on which the ROC curve for recognition
of experimentally confirmed high-affinity ligand receptor
pairs in the set of all 157 9 17 = 2,669 possible pairs is
shown in grey. This type of analysis relies on the ability of
the model to deliver comparable values of the docking
scores of a single ligand to multiple receptors. Comple-
menting the ligand docking scores with the pre-determined
NR-specific binding energy offsets further improved ligand
selectivity prediction. The histogram of per-ligand AUC
values with and without the offset correction is shown in
Fig. 6b. The AUC of 100 for a selected compound is an
evidence of perfect compound selectivity profile recogni-
tion, i.e. the situation in all compound/target-receptor pairs
are predicted with better scores than compound/non-target-
receptor pairs. As shown in Fig. 6b, the prefect profile
recognition was achieved for 53 of 124 compounds without
the offsets, and for 66/124 compounds with the offsets.
Figure 7 presents a good agreement of the activities pre-
dicted by docking with annotated experimental compounds
activities. For example, cortisol (Ligand No 46 in the
Fig. 8) is known as to be an agonist of GR and T877A AR,
which does not bind to wtAR. This profile is correctly
predicted by our ensemble docking. Another example is
asoprisnil (Ligand No 55), agonist of PR, which does not
bind to ER and MR. Biological activity of asoprisnil was
well characterized by predicting binding energy in our
Table 2 Successful self- and cross-docking of crystallographic
compounds into individual pockets of the proposed NR pocket library







wtMR? 0.65±0.60 100 100
S810LMR? 0.35±0.07 100 100
TRb? 0.44±0.06 93 91
PR? 0.56±0.12 55 33
GR? 0.62±0.25 100 100
RARc? 0.80±0.41 100 100
PPARd? 1.20±0.41 55 33
PPARa? 0.65±0.56 75 75
PPARc? 0.77±0.50 73 62
VDR? 1.31±0.60 100 100
RXRa? 0.61±0.27 76 70
wtAR? 0.38±0.12 93 91
T877AAR? 0.52±0.38 66 50
ERa- 1.17±0.59 68 58
ERa? 1.13±0.59 75 66
ERb- 0.75±0.45 66 50
ERb? 0.38±0.14 88 83
RMSD of self-docking is described by average across all pockets in
the ensemble ± standard deviation
J Comput Aided Mol Des (2010) 24:459–471 465
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MRC model. The patterns observed in Fig. 7 may also
reveal potentially complex cross-reactivity profiles of the
NR ligands and provide explanation for the off-target
activities or side effects of the studies ligands. Experi-
mental validation of these predictions would allow further
refinement of the method.
The obtained results confirm the applicability of the NT
binding pocket ensembles in the task of compound selec-
tivity profiling.
Discussion
Proteins are flexible machines that exist in a dynamic
conformational equilibrium in solution. They tend to
change their conformation, often significantly, to
accommodate binding of ligands (the so-called induced fit
effect). Multiple receptor conformation (MRC) docking
[20], with its faster 4D incarnation [21], represent one
possible approach to incorporation of receptor flexibility in
ligand docking. With the rapid growth of structural infor-
mation in the form of X-ray crystal structures and NMR, it
becomes possible to design multi-conformational pocket
libraries that provide the unique possibilities for structure-
based drug design.
Nuclear receptors form a major class of drug targets.
They are involved in a variety of human diseases including
cancer, hormonal disorders, and diabetes. In order to
understand the structural basis of selectivity of NR-targeting
existing drugs, and to develop novel selective nuclear
receptor modulators, it is important to build a comprehen-
sive panel of 3D pockets with their conformational varia-
tions. In this work we present the first such panel consisting
of 17 ensembles of binding pockets of 13 different receptors.
We tested ability of the designed ensembles to correctly
reproduce the compounds binding poses, draw a distinction
between the active compounds and other NR ligands in
virtual screening, and predict compound selectivity profiles.
Table 3 Accuracy of VLS in single receptor mode measured by their ROC AUC values
Receptor PDB ID ROC % Receptor PDB ID ROC % Receptor PDB ID ROC %
ERa- 1xp6 71 PR? 1zuc_b 60 PPARa? 2npa_c 88
1xqc_c 82 1e3k_a 75 2p54 78
1sj0 73 2ovh 88 2rew 83
2ouz 89 RARc? 1exa 97 1k7l_a 92
ERa? 2b1v_a 85 1fcx 96 PPARd? 1y0s_a 95
2fai_a 80 2lbd 95 1gwx_a 97
1l2i_a 81 RXRa? 2p1u 90 2j14_b 99
2b1z_a 80 1rdt 92 PPARc? 1rdt 89
ERb- 1hj1 90 1mzn 88 1nyx 86
1qkn 75 1fm9 86 1k74 89
1qkm 61 1xvp 92 1knu 90
ERb? 1u3r_a 96 VDR? 1db1 96 2f4b 87
1yy4_a 98 1txi 78 2gtk 91
1zaf_b 97 2has 97 TRb? 2h6w 93
GR? 1m2z_a 80 1s19 76 1n46_b 93
1p93_a 75 2har 76 1q4x 93
3bdq 65 2hb7 92 1nax 91
wtMR? 2aa7 98 wtAR? 2hvc 81
2a3i 96 1e3g 81
2aa2 99 1t7t 87
S810LMR? 1y9r_a 80 2am9 83
1ya3_a 95 T877AAR? 1gs4 89
2aa6_a 91 2oz7 87
2aax_a 93 2ax7 87
The crystal structure 1rdt is a heterodimer of PPARc and RXRa and was used separately for both receptors
b Fig. 3 Comparison of the top-scoring docking pose of the crystal-
lographic ligands in the pocket ensembles of their target NR
(magenta) with their crystallographic poses (grey). *The correct
geometry was found within three top-scoring poses. For each pose, n
is number structures in the ensemble and d is the Rmsd between the
native and docking poses
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The collected NR pocket ensembles reproduced the
near-native ligand binding geometry as the top-scoring
pose in 78% of the cases in the single receptor docking
mode, and in 89% of the cases in the ensemble mode.
The high success rate ensemble docking suggests that the
obtained models may be good starting points for
optimization of the existing compounds or virtual ligand
screening.
Most NR models demonstrated high screening selec-
tivity even in single rigid receptor mode. The selectivity
was further improved by combining them in the ensemble
mode. The high selectivity of all 17 ensembles towards
Fig. 4 Comparison of VLS accuracy in single and multiple receptor modes, as measured by the areas under the ROC curves. ROC curves of
single and multiple receptor docking are shown in red and blue, respectively. ?; agonist, -; antagonist, MRC; Multiple Receptor Conformation
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their active ligand is exemplified by the ROC-AUC values
above 80%; for 11 ensembles, it exceeded 90%. All
receptors recognized most of their active ligands in top
2–10% of the hit list.
Selectivity between different isoforms of the same
receptor can represent an important parameter of under-
standing the binding mode of agonists and antagonists.
Here, we built pocket ensembles of PPAR a, d, c and ER a,
b, and evaluated their ability to discriminate between iso-
type-specific ligands in virtual screening. All three pocket
ensembles of PPAR (a, d, and c), recognized their known
agonist and antagonists with high selectivity (91, 98 and
88% respectively). Ensembles of ER a, b also showed high
selectivity even though the structures of their ligand
binding domains are very similar. Further on, the confor-
mation-specific ensembles of ERa, and ERb were also used
to test the selectivity between different conformational
states of the same protein. The active and inactive
ensembles successfully distinguished agonists from antag-
onists and vice versa. The obtained results suggest that our
proposed pocket ensemble library can potentially be used
as a powerful device for structure-based discovery of novel
specific nuclear receptor modulators with the desired
mechanism of action.
Furthermore, by combining the compound docking





ERα- -6.9  -5.7 
ERα+ -12.8  -9.2 
ERβ- -5.1  -1.3 
ERβ+ -7.9  -12.9 
GR+ 0.1  6.4 
S810LMR+ 2.0  1.7 
wtMR+ 4.8  7.2 
PR+ 0.7  5.8 
RARγ+ 7.0  -1.1 
RXRα+ 8.3  9.0 
VDR+ 1.1  -3.4 
wtAR+ -3.3  -3.1 
T877AAR+ -6.7  -4.9 
PPARα+ -0.2  1.4 
PPARδ+ 8.0  4.2 
PPARγ+ 2.4  0.1 
TR+ 8.4  5.7 
Fig. 5 Comparison of receptor-
specific binding energy offsets
derived by naı¨ve method and by
machine learning
Fig. 6 Recognition of correct receptor-ligand binding pairs and
ligand profiling using the proposed NR pocket ensemble library:
a overall ROC curve with and without receptor-specific offsets;
b histogram of per-compound AUC values. AUC value of 100
indicates perfect correspondence between the predicted and the
experimentally determined compound activity
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energy offsets, we showed that our proposed pocket
ensembles can be used for in silico determination of
compound selectivity profiles. This aspect is extremely
important as it can open avenues for rational prediction of
possible off-target effects of the experimental compounds,
or for repurposing of the existing drugs [22, 43, 44].
Conclusion
In this work, we presented a comprehensive library of three
dimensional models of the nuclear receptor binding pock-
ets in different functional states. Using the library, we
validate and demonstrate the advantage of using the
ensemble docking approach in various structure-based drug
discovery applications, including compounds pose predic-
tion, virtual screening, and selectivity profiling.
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